Friday, July 10, 2026

Drug profile · INN

besilesomab

besilesomab (SCINTIMUN) is a diagnostic agent. Associated with Telix Innovations.

EMA: approved Various (V09) V09HA03
Patents linked 1
Pipeline programs 1
News articles 0
Drug details — besilesomab

Quick answer

besilesomab (SCINTIMUN) is a diagnostic agent. Associated with Telix Innovations.

Key facts

INN besilesomab
Brand SCINTIMUN
Mechanism Diagnostic agent
Therapeutic class Various (V09)
ATC code V09HA03

Mechanism of action

Diagnostic agent

Approval history

Authority Status Date
EMA approved

Pipeline programs

  1. Standard Care Intervention (SCI) Phase 3 · BRIGHT MINDS BIOSCIENCES · Tobacco Dependence

Related & competitor drugs

  1. deferasirox Various (V03)
  2. ferric citrate coordination complex Various (V03)
  3. folic acid Various (V04)
  4. sevelamer carbonate Various (V03)
  5. sugammadex sodium Various (V03)
  6. cobicistat Various (V03)
  1. US 12383636

    Marking precursor with squaric acid coupling

    Expires Mon Aug 07 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

Frequently asked questions

What is besilesomab?

besilesomab (SCINTIMUN) is a diagnostic agent. Associated with Telix Innovations.

What is the brand name for besilesomab?

SCINTIMUN is a marketed brand name for besilesomab. Check FDA Drugs@FDA for the current US label holder and prescribing information.